monitor- ing of MTX is its use in high doses (HDMTX) for adjuvant therapy ... renal function, advanced in age, and taking ..... tumor kill as well as host toxicity.
Clinical
Chemistry
1322-1329
42:8(B)
(1996)
Concepts in use of high-dose methotrexate therapy STEVEN
P. TREON and BRUCE A. CHABNER*
In cancer chemotherapy, routine monitoring of drug concentrations has been practical only for methotrexate (MTX). The primary setting for pharmacokinetic monitoring of MTX is its use in high doses (HDMTX) for adjuvant therapy of osteosarcoma, for single-agent treatment of intracranial lymphomas, and in combination therapy of childhood leukemia as well as adult and pediatric non-
mas, and certain adult non-Hodgkin lymphomas, particularly those of the Burkitt type [1_4].1 Although methotrexate (MTX) is used in the treatment of many malignancies, the benefit of using HDMTX ( 1 g/m2), as opposed to conventionally dosed MTX (
